Cosmo Surges 40% on Baldness Candidate’s Phase III Data
Images of the scalps of two patients treated with the 5% formulation of Cosmo Pharmaceuticals’ androgenetic alopecia (AGA)…
After 1- and 6-Month Gains, Gene Editing Companies Await Q3 Results
As developers of gene editing therapies and other genetic medicines get set to report third quarter earnings in…